Table 2 Oncological outcomes of the patients who were treated with focal therapy with high-intensity focused ultrasound.
Low-risk groupa (n = 51) | Intermediate-risk group (n = 107) | High-risk group (n = 82) | P-value | |
|---|---|---|---|---|
Nadir value of serum PSA level (ng/mL) | 1.52 (0.10–4.86) | 1.11 (0.07–8.97) | 1.14 (0.04–11.56) | 0.235 |
Decreased rates of serum PSA level | 73% (7.0–99) | 81% (22–99) | 83% (14–99) | 0.034 |
Biochemical failure free-survival ratesb | 92.2% | 89.7% | 85.4% | 0.443 |
Pathological failure free-survival rates | 93.7% | 91.6% | 86.6% | 0.445 |
Rates of pathological recurrence in treated area | 0% (0 cases) | 0% (0 cases) | 0% (0 cases) | - |
No. of repeat focal therapy of the patients with pathological failure | 3.9% (2 cases) | 4.7% (5 cases) | 2.4% (2 cases) | 0.724 |
Radical or systematic treatment free rates | 96.1% | 94.4% | 95.1% | 0.900 |
Follow-up periods (months) | 54 (24–84) | 48 (24–84) | 48 (24–84) | 0.004 |
